All Organ-on-a-Chip articles
-
ArticleOrgan chips move closer to drug discovery pipelines
From uncovering new drug targets to predicting human toxicity, organ chips are showing what they could bring to drug discovery. Professor Donald Ingber of Harvard University discusses where the technology is heading next.
-
NewsAccessible multiplex imaging workflow advances spatial liver disease research
A new multiplex immunofluorescence workflow using standard laboratory equipment and open-source software enables detailed spatial analysis of liver tissue, organoids and organ-on-a-chip models, lowering barriers to advanced spatial biology in hepatology research.
-
InterviewThe global push to reduce animal testing in drug development
Non-animal methods are already used throughout early drug discovery, yet animal testing continues to dominate regulatory safety assessment. Recent initiatives suggest change is coming, but significant scientific and practical challenges remain.
-
ArticleWhy targeted therapies are exposing the limits of animal models – and what comes next
Traditional preclinical models are struggling to keep pace with a new generation of targeted therapies. As regulators embrace new approach methodologies (NAMs), vascularised tissue platforms are offering a more human-relevant approach to predicting drug efficacy and safety.
-
NewsHow researchers are recreating the human heart in the lab
Many promising therapies fail because preclinical models do not fully capture the complexity of the human heart. A new review explores how 3D cardiac constructs could improve disease modelling, drug screening and safety assessment.
-
NewsC-Path launches coalition to advance human-relevant drug discovery
The New Approach Methodologies Developer Coalition brings together technology developers, pharmaceutical companies and regulators in a precompetitive initiative to establish qualification standards for complex in vitro models, microphysiological systems and related human-relevant technologies.
-
ReportOrganoids and Organ Chips: Improving Decision-Making in Early Drug Discovery
Traditional preclinical models do not always predict what will happen in patients. This report explores how organoids, organ-on-chip systems and advanced imaging are being used to generate more clinically relevant insights and support better decision-making earlier in drug discovery.
-
NewsOvarian follicles provide new platform for angiogenesis research
A novel microphysiological system using ovarian follicles enables physiologically relevant three-dimensional angiogenesis modelling within 24 hours, offering improved drug screening capabilities that distinguish therapeutic effects from general toxicity.
-
NewsELRIG announces keynote speakers for Advances in Cell-based Screening 2026 in Gothenburg
ELRIG has announced the keynote speakers for its 2026 Advances in Cell-based Screening conference in Gothenburg, where scientists will gather to explore how human-first models, advanced cell biology and AI are changing the future of drug discovery.
-
ArticleReplacing animals in science: what the UK’s new strategy means
The UK has set out a strategy to replace animal testing, but delivering change will depend as much on regulation as on technology. Dr Emma Grange, Director of Science and Regulatory Affairs at Cruelty Free International, examines what the policy signals for research, drug discovery and safety assessment.
-
NewsDrug Target Review’s women in STEM
For International Day of Women and Girls in Science, Drug Target Review highlights articles published over the past year that were authored by women, celebrating their contributions to research.
-
NewsNew paper warns against phasing out animal testing too quickly
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
-
ArticleDrug development in 2026: NAMs, safety and regulatory changes
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
-
NewsHydrogel tech enables global shipping of organoid models
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
-
NewsNew organ-on-a-chip captures ageing immune responses to cancer vaccines
Scientists have developed an organ-on-a-chip platform that replicates age-related immune decline, offering a long-missing tool for testing cancer vaccines in older adults.
-
NewsAutomated lung organoids to speed up new drug development
Scientists have developed an automated method to grow lung organoids, with the hope of speeding up drug testing, reducing reliance on animal models and helping to develop new personalised treatments.
-
ArticleTackling the organ shortage through vascular bioengineering
Frontier Bio’s vascular bioengineering research connects tissue modelling with graft development to advance regenerative medicine and drug discovery.
-
NewsUK Government announce plans to phase out animal testing for drugs
The UK government have announced a new strategy to phase out animal testing in scientific research, aiming to replace traditional experiments with innovative human-relevant methods such as organ-on-a-chip systems and AI analysis.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
NewsLeukaemia-on-a-chip mimics bone marrow for better CAR T testing
A new “leukaemia-on-a-chip” device replicates human bone marrow and immune interactions, enabling researchers to observe CAR T cell therapies in action - potentially allowing for more personalised treatment strategies for leukaemia patients.